Histiocytosis encompasses a group of diverse disorders with a common primary event: the accumulation and infiltration of monocytes, macrophages, and dendritic cells in the affected tissues. Such a description excludes diseases in which infiltration of these cells occurs in response to a primary pathology. The clinical presentations vary greatly, ranging from mild to life threatening. Although nearly a century has passed since histiocytic disorders were recognized,[1] their pathophysiology remains an enigma, and treatment is nonspecific. These problems underscore the need for an improved understanding of the etiology and pathogenesis of histiocytosis.

Over the past 50 years, the nomenclature used to describe histiocytic disorders has substantially changed to reflect the wide range of clinical manifestations and the variable clinical severities of some disorders that have the same pathologic findings. For example, the entity now referred to as Langerhans cell histiocytosis (LCH) was initially divided into eosinophilic granuloma, Hand-Schüller-Christian disease, and Letterer-Siwe disease, depending on the sites and severity. Later, these were found to be manifestations of a single entity and were unified under the term histiocytosis X.[2] Most recently, this designation was changed to Langerhans cell histiocytosis to reflect the recognition of the primary cell involved and the pathophysiology of the disease.[3, 4] Although several histiocytic disorders are briefly discussed in this article (see History), the primary focus is on Langerhans cell histiocytosis.


Improved understanding of the pathology of histiocytic disorders requires knowledge of the origins, biology, and physiology of the cells involved. Normal histiocytes originate from pluripotent stem cells, which can be found in bone marrow.[5] Under the influence of various cytokines (eg, granulocyte-macrophage colony-stimulating factor [GM-CSF], tumor necrosis factor-alpha [TNF-alpha], interleukin [IL]-3, IL-4), these precursor cells can become committed and differentiate to become a specific group of specialized cells. Committed stem cells can mature to become antigen-processing cells, with some possessing phagocytic capabilities. These cells include tissue macrophages, monocytes, dendritic cells, interdigitating reticulum cells, and Langerhans cells. Pluripotent stem cells can also be committed to produce dendritic cells. Each category of histiocytosis can be traced to reactive or neoplastic proliferation and disorder of cells in one of these groups.[6]

The importance of dendritic cells in presenting antigens to T and B lymphocytes is increasingly recognized. Dendritic cells appear to develop in several pathways. Immature dendritic cells respond to GM-CSF (not to macrophage colony-stimulating factor [M-CSF]) and become committed to generating dendritic cells, which are “professional” antigen-presenting cells (APCs).[7] These cells can capture antigen and migrate to lymphoid organs, where they present the antigens to naive T cells.[8] Dendritic cells are also efficient stimulators of B-cell lymphocytes.[9]

Effective induction of antigen-specific T-cell responses requires interaction between the dendritic cells and T lymphocytes to prime the latter cells for expansion and appropriate function. The surface of the APC contains 2 peptide-binding proteins (ie, major histocompatability complex [MHC] classes I and II), which can stimulate cytotoxic T (TC) cells, regulatory T (Treg) cells, and helper T (TH) cells.[10] Although circulating T-cell lymphocytes can independently recognize antigens, their number is small. Dendritic cells display a large amount of MHC-peptide complexes at their surface and can increase the expression of costimulatory receptors and migrate to the lymph nodes, spleen, and other lymphoid tissues, where they activate specific T cells.

The first signal may involve interaction between an MHC I–bound and/or MHC II–bound peptide on an APC with the T-cell receptor (TCRs) on the effector lymphocytes. TCRs can recognize fragments of antigen attached to MHC on the surface of an APC. Costimulatory interaction (ie, second signal) is between CD80(B7.1)/CD86(B7.2) on the dendritic cell, with CD28 on the T cells.[11, 12, 13] A combination of the 2 signals activates the T cell, resulting in upregulation of the expression of CD40L, which, in turn, can interact with the dendritic cell–expressed CD40 receptor.[10] In perforin-deficient mice, abnormally heightened cytokine production by T cells is due to overstimulation by APCs after a viral infection.[14]

This cell-to-cell interaction between dendritic cells and T cells generates an antigen-specific T-cell response. The effective function of antigen presentation by dendritic cells is presumed to reflect that these cells, in addition to MHC molecules, express a high density of other costimulatory factors. Dendritic cells can produce several cytokines, including IL-12, which is critical for the development of TH 1 cells from naive CD4+ T cells.[11, 12]

Ligation of CD40 on dendritic cells triggers the production of large amounts of IL-12, which enhances T-cell stimulatory capacity. This observation suggests that feedback to dendritic cells results in signals that are critical for induction of immune responses. The nature of the latter interaction and requirement for optimal dendritic cell activation is not fully understood. Dendritic cells in culture derived from human blood monocytes exposed to GM-CSF and IL-4 followed by maturation in a monocyte-conditioned medium have heightened antigen-presenting activity.[15, 16] Monocyte-conditioned media contain critical maturation factors to catalyze this process.

Dendritic cells are present in tissues in a resting state and cannot stimulate T cells. Their role is to capture and phagocytize antigens, which, in turn, induce their maturation and mobilization.[17, 18, 19, 20] Immature dendritic cells reside in blood, lungs, spleen, heart, kidneys, and tonsils, among other tissues. Their function is to capture antigen and migrate to the draining lymphoid organs to prime CD4+ and CD8+ T cells. In the process of their function, these cells mature and increase their capacity to express costimulatory receptors and decrease their capacity to process antigen. These cells can phagocytize, forming pinocytic vesicles for sampling and concentrating their surrounding medium, which is called macropinocytosis.[21]

Immature dendritic cells express receptors that mediate endocytosis, including C-type lectin receptors, such as the macrophage mannose receptor and DEC205, FC-gamma, and FC-epsilon receptors.[7] Microbial components, as well as IL-1, GM-CSF, and TNF-alpha, have an important role in cellular response[22, 23, 24] and can stimulate maturation of dendritic cells, whereas IL-10 opposes it.[25]

Mature dendritic cells possess numerous fine processes (veils, dendrites) and have considerable mobility. These cells, rich in MHC classes I and II, have abundant molecules for T-cell binding and co-stimulation, which involves CD40, CD54, CD58, CD80/B7-1, and CD86/B7-1. Mature dendritic cells express high levels of IL-12. High levels of CD83 (a member of the immunoglobulin [Ig] superfamily), and p55 or fascin (an actin-bundling protein) are present in these cells, as opposed to the low levels that are present in the immature cells.[7]

IL-1 enhances dendritic cell function. This effect appears to be indirect and due to activation of TNF receptor–associated factors (TRAFs). Mature dendritic cells also express high levels of the NF-kappaB family of transcriptional control proteins. These proteins regulate the expression of several genes encoding inflammatory and immune proteins. Signaling by means of the TNF-receptor family (eg, TNF-R, CD40, TNF-related activation-induced cytokine [TRANCE], receptor activator of NF-kappaB [RANK]) activates NF-kappaB. Immunologic response of dendritic cells to a given antigen partly involves the triggering of signal-transduction pathways involving the TNF-R family and TRAFs.

Information regarding the fate of dendritic cells after these events is sparse. Dendritic cells disappear from the lymph nodes 1-2 days after antigen presentation, possibly because of apoptosis.[26] CD95 (Fas) is suggested to have a role in the death of the dendritic cell.[27, 28] Although dendritic cells express CD95, CD95 ligation does not induce apoptosis.[29]

Experiments indicate that immature dendritic cells are partially susceptible to death receptor–mediated apoptosis.[30] TNF-related apoptosis-inducing ligand (TRAIL) may bind to 5 separate receptors. Functional cytoplasmic death domains characterize TRAIL-R1 receptors, TRAIL-R2 receptors, and CD95 receptors. In contrast, TRAIL-R3 is a membrane-anchored truncated receptor, and TRAIL-R4 does not have a functional death domain. Dendritic cells express CD95, TRAIL-R2, and TRAIL-R3 in comparative levels. Similar to the role of CD95L, that of TRAIL-mediated apoptosis of mature dendritic cells has been controversial. Data regarding in vitro TRAIL-mediated apoptosis in these cells has been reported[31] and disputed.[30] Mature dendritic cells are resistant to TRAIL- and CD95L-mediated apoptosis.[30]

C-FLIP, which is the caspase-8 inhibitory protein capable of inhibiting death receptor–mediated apoptosis, is highly expressed in mature dendritic cells, whereas only low levels are found in immature cells.[30] Overexpression of C-FLIP inhibits signals of death receptor.[32] C-FLIP expression on dendritic cells is upregulated during maturation.[29] Note that engagement of CD95 on immature dendritic cells by CD95L induces phenotypic and functional maturation of these cells.

In addition, a CD95-activated dendritic cell upregulates the expression of MHC class II and costimulatory receptors, which is essential for the function of these cells. Furthermore, such engagement upregulates the expression of dendritic-cell lysosome-associated membrane protein (DC-LAMP) and causes the secretion of proinflammatory cytokines, including IL-1 beta and TNF-alpha.[33]

The function of normal Langerhans cells is cutaneous immunosurveillance. These cells can migrate to the regional lymph nodes and potentially present antigen to paracortical T cells and cause their transformation to interdigitating dendritic cells. Some cancer cells disrupt dendritic-cell function, blocking the development of tumor-specific immune responses and allowing tumors to evade recognition.[34, 35] To counteract this effect, dendritic cells may produce the antiapoptotic protein Bcl-xL.[35] Stimulation of dendritic cells by CD154, IL-12, or IL-15 increases expression of this protein. The information gained from normal physiology of dendritic cells may potentially lead to treatment modalities for histiocytic disorders.




The incidence of Langerhans cell histiocytosis is 4-5.4 per million population. However, because many bone and skin lesions may not be diagnosed as Langerhans cell histiocytosis, this rate may be an underestimate.[36] The estimated incidence of neonatal Langerhans cell histiocytosis, determined by using the population-based German Childhood Cancer Registry, is 1-2 per million neonates.[37]


See History.


The overall male-to-female ratio is 1.5:1. The male-to-female ratio in individuals who have a single organ system involvement is 1.3:1, and the male-to-female ratio in individuals with multisystem disease 1.9:1.[38]


The disease can occur in individuals of any age. Langerhans cell histiocytosis can be congenital[39, 40] or may occur in adults.[41] The disease is seen in all age groups, ranging from neonates to adults.[42, 43, 44, 37] The incidence peaks in children aged 1-3 years.[45] In one study, the age at diagnosis was 0.09-15.1 years. Patients with single system involvement were older (0.1-15.1 y) than those with multisystem involvement (0.09-14.8 y).[38]


Langerhans cell histiocytosis (LCH) can be local and asymptomatic, as in isolated bone lesions, or can involve multiple organs and systems, with clinically significant symptoms and consequences.[46] The clinical manifestations depend on the site of the lesions and on the organs and systems involved and their functions (see Physical).


Classification of diseases involving histiocytic and dendritic cells is difficult, and classification systems must include a broad range of diseases. Therefore, most systems have been incomplete and arbitrary. The location of lesions and the extent of the disease substantially affect the course of the disease and the patient's prognosis. Decisions regarding treatment are based on the extent of the disease.

Classification of the World Health Organization

Table 1 shows the classification of histiocytic and dendritic cell disorders the World Health Organization (WHO) proposed.[47]

Table 1. Classification of Histiocytosis Syndromes in Children

View Table

See Table

The WHO classification of neoplastic disorders of histiocytes and dendritic cells is as follows:

Classification of the Histiocyte Society

Table 2 shows the working classification of histiocytosis syndromes from the Histiocyte Society.

Table 2. Histiocyte Society Classification of Histiocytosis Syndromes

View Table

See Table

The following, adapted from the Writing Group of the Histiocyte Society, describes confidence levels for the diagnosis of class I Langerhans cell histiocytosis:[3]

Previous and other classifications

Langerhans cell histiocytosis formerly was divided into 3 disease categories: eosinophilic granuloma, Hand-Schüller-Christian disease, and Letterer-Siwe disease, depending on the severity and extent of involvement. This classification and its related risk groups no longer are used. Systems based on these categories were meant to reflect the extent of involvement and its relationship to the patient's prognosis.[1, 14]

Some classifications simply divide histiocytic disorders into class I Langerhans cell disease, class II nonLangerhans cell histiocytic disease without features of malignant disorders, and class III malignant histiocytic disorders.

A clinical-grouping system for Langerhans cell histiocytosis based on age, extent of the disease, and organ dysfunction, as once constructed,[48] can provide a means to compare patient data and prognoses. Various categories, such as restricted and extensive multiorgan involvement, have also been proposed. Data regarding treatment results are needed to validate any classification system.

The Histiocyte Society developed a classification based on risk groups that arose from the first and second international (Langerhans cell histiocytosis I and II, respectively) trials of chemotherapy.[49] At-risk organs and systems identified in those trials included the liver, lung, spleen, and hematopoietic system. This risk classification is used in the treatment protocol of the third international study for Langerhans cell histiocytosis (Langerhans cell histiocytosis III).

Patients are stratified into 3 groups: (1) at-risk patients, or those with multisystemic involvement including 1 or more at-risk organs; (2) low-risk patients, or those with multisystem involvement not including at-risk organs; and (3) other patients, or those with single-system multifocal bone disease or localized involvement of special sites (intraspinal extension or involvement of the paranasal, parameningeal, periorbital, or mastoid region) that can lead to persistent soft-tissue swelling.

In the trial, at-risk patients are randomly assigned to 1 of 2 treatment arms. Low-risk patients receive standard therapy for 6-12 months, and those with multifocal bone or special-site involvement receive the standard therapy for 6 months.

Other Histiocytoses

Although this article focuses mainly on Langerhans cell histiocytosis, other histiocytoses are as follows:


When the disease is focal, establishing the diagnosis of Langerhans cell histiocytosis depends on a high level of suspicion. When advanced multisystem involvement is observed, diagnosis is often easy. Adequate workup to determine the extent of the disease and possible complications is essential. Biopsy and pathologic evaluation are needed to establish the diagnosis.


The causes of most histiocytoses are not known. Factors implicated in the etiology and pathophysiology of these disorders include infections, especially viral infections;[105] Cellular and immune dysfunction,[106, 107] including dysfunction of lymphocytes and cytokines;[108, 109, 110] neoplastic mechanisms; genetic factors;[111, 5, 112, 113, 114, 115, 116, 117] cellular adhesion molecules;[118, 119, 120] and their combinations. Although human herpes virus 6 has been found in lesions of Langerhans cell histiocytosis, its etiologic significance has been questioned.[118, 121, 122] Extensive searches for evidence of viral infection have been unrevealing.[37]

Laboratory Studies

Laboratory investigations and diagnostic tests should partly be tailored to the extent of disease suspected on the basis of the patient's history and physical findings.

Table 3 shows minimal frequencies of follow-up. Testing more frequent than that shown might be necessary.

Table 3. Laboratory and Imaging Studies in Patients With Langerhans Cell Histiocytosis (LCH)*

View Table

See Table

Table 4 lists the indications for various laboratory evaluations, with the minimal frequencies of follow-up. Testing more frequent than that shown might be necessary.

Table 4. Indication for Laboratory Evaluations Based on Findings in Langerhans cell histiocytosis

View Table

See Table

Imaging Studies

See Table 3-4 for appropriate imaging studies when Langerhans cell histiocytosis is suspected.

Radiographic imaging of lytic lesions of the skull reveals a punched-out pattern without evidence of periosteal reaction or marginal sclerosis, shown below.

View Image

Radiograph of lytic lesions of the skull reveals a punched-out pattern without evidence of periosteal reaction or marginal sclerosis.

Radionuclide bone scanning with technetium-99m polyphosphate may reveal a localized increased uptake. This study is complementary to plain radiography.

MRI sometimes helps in identifying lesions that cannot be detected with other modalities. For example, in one study, 28% of children with Langerhans cell histiocytosis had MRI findings suggestive of neurodegenerative disease.[71]

Neurologic findings may not always be correlated with the MRI results and may lag behind findings on MRI.[144]

CT and MRI can show the detailed anatomic pattern of involvement and can help in staging the disease.[145]

Positron emission tomography (PET) with 18F-fluoro-deoxyglucose (FDG) may be an effective tool for evaluating LCH and may provide additional information regarding the activity of the lesions.[146] However, this ability has not been definitively studied.

With pulmonary involvement, CT scanning is the best modality to reveal cysts and micronodular infiltrates.

Other Tests

When pulmonary involvement occurs, pulmonary function may be abnormal.[99, 31]

Pulmonary function tests are critical components of follow-up in patients with pulmonary involvement.


Biopsy is needed to establish the diagnosis of Langerhans cell histiocytosis.

Histologic Findings

Regardless of the clinical severity, the histopathology of Langerhans cell histiocytosis is generally uniform. To some extent, the location and age of the lesion may influence the histopathology of the disease.[147] Early in the course of the disease, lesions tend to be cellular and contain aggregates of pathologic Langerhans cells (PLCs), intermediate cells, interdigitating cells, macrophages, T cells, and giant histiocytes. Mitotic figures number 0-23 per 10 high-power fields.[15]

Multinucleated giant cells are common, and some may exhibit phagocytosis. Lesions may also include eosinophils, necrotic cells, and Langerhans cell histiocytosis cells. With time, the cellularity and number of Langerhans cell histiocytosis cells are reduced, and macrophages and fibrosis become eminent. The infiltrates tend to destroy epithelial cells. Table 5 shows the phenotypes and cell-marker characteristics of Langerhans cell histiocytosis.

Table 5. Cell Markers and Phenotypes of Histiocytic and Related Disorders

View Table

See Table

Table 6 shows specialized stains for diagnosing these disorders, and Table 7 shows labeling pattern of histiocytes and dendritic cells.

Table 6. Stains for Diagnosing Histiocytosis

View Table

See Table

Table 7. Labeling Pattern of Histiocytes and Dendritic Cells

View Table

See Table

Langerhans cells express CD1a antigen, HLA-DR, and a subunit S-100 protein. See the image below.

View Image

Photomicrograph shows sample of Langerhans cell histiocytosis (LCH) that immunocytochemically stains positive for S-100 protein.

Upon morphologic evaluation, cells are 12 µm in diameter with moderately abundant cytoplasm and a medium-sized folded, indented, or lobulated nucleus that has vesicular chromatin with 1-3 nucleoli and an elongated central groove producing a coffee-bean appearance.[148, 149, 150]

The histopathology of the Langerhans cell histiocytosis does not appear to be prognostic of the outcome of the disease.[15] The aggregation of Langerhans cells is observed in various disorders, such as lymphomas (eg, Hodgkin disease), lung cancer, and thyroid cancer. However, these disorders are secondary and resolve with control of the primary disorder.[4, 151]

In Langerhans cell histiocytosis, the cytoplasm and, rarely, the nucleus contain the characteristic structures termed Birbeck granules, shown below.

View Image

Transmission electron micrograph shows a diagnostic rod-shaped Langerhans Birbeck granule.

These trilaminar organelles are 190-360 nm long and approximately 33 nm wide, with a central striated line. These are derived from cytoplasmic membrane and are involved in receptor (T6)-mediated and non–receptor-mediated endocytosis. An electron microscopic finding of racquet-shaped granules in the cells can be helpful in confirming the pathologic diagnosis.

Relatively nonspecific findings include cytoplasmic, trilaminar, membranous loops and laminated substructures of lysosomes.[152] Langerin is a type II transmembrane C-type lectin associated with formation of Birbeck granules. This can be used as a selective marker for Langerhans cells and cells involved in Langerhans cell histiocytosis. Langerin expression is present in most cases of Langerhans cell histiocytosis.[153] Immunohistochemical determination of Langerin and CD1a may be used to separate Langerhans cell histiocytosis from other histiocyte proliferations.

Birbeck granules are the products of internalization of complexes originating from cell-membrane antigens and corresponding antibodies. CD1a antigen can be detected in paraffin-embedded tissues to provide for reliable diagnostic testing.[154, 155] ATPase peanut lectin and alpha-D-mannoside can be positive in the dendritic reticulum. An electron microscopic finding of racquet-shaped granules in the cells can be helpful to confirm the pathologic diagnosis.[156] Enzyme histochemistry and immunocytochemistry can also aid in the diagnosis of histiocytosis.[41]

The organs and tissues most commonly involved are the bones, skin, lymph nodes, bone marrow, lungs, hypothalamic-pituitary axis, spleen, liver, GI tract, and orbits. Multisystemic involvement is common.[20] Bones can be involved in isolation or as a part of multisystemic disease. The skull or large bones are often involved. Bone lesions may contain an accumulation of eosinophils, multinucleated giant histiocytes, necrosis, and hemorrhage. The term eosinophilic granuloma was previously used to describe single bone lesions of Langerhans cell histiocytosis.

Cutaneous involvement can also be singular or can be a part of generalized involvement.[92, 93, 94, 95] A spontaneously regressing nodular form of cutaneous Langerhans cell histiocytosis is reported in infants; it involves deep dermis with a nodular aggregate of histiocyte and is called congenital self-healing reticulohistiocytosis.[96, 97, 98] In general, skin lesions have a pattern of diffuse or multifocal nodular aggregation of PLCs deep in the papillary dermis; destruction of epidermal-dermal interface; and infiltration of histiocytes, T-cell lymphocytes, and eosinophils. The lymph nodes and thymus can be involved as a primary site or as a part of multiorgan and systemic involvement. The most common sites are the cervical, inguinal, axillary mediastinal, and retroperitoneal areas.[101, 157]

Five histologic motifs have been recognized. These include sinusoidal, limited sinusoidal, epithelioid granulomatous, partial effacement, and total effacement. However, the prognostic significance of these appearances is not proven. The cellular composition includes Langerhans cells, macrophages, multinucleated giant histiocytes, T lymphocytes, and eosinophils.[148, 149] Histologic involvement may have different appearances in lesions from separate sites. In some instances, lymph nodes are massive and cause airway obstructions.

Suppuration resembling infection has been reported.[102] The bone marrow may be normal or heavily involved. Bone marrow lesions may be focal with pathologic infiltration of Langerhans cells or may contain neutrophils, eosinophils, lymphocytes, multinucleated cells, fibrosis, and (in rare cases) eosinophilic accumulation. Pulmonary involvement is more common in adults than in children (especially adults with a history of smoking), but it occurs in 20-40% of all patients.[99, 31] Small cysts can coalesce and rupture into the pleural cavity, leading to pneumothorax.[100]

CNS involvement, including pituitary involvement, is often part of systemic disease.[158, 159, 160] The CNS is rarely a primary site of Langerhans cell histiocytosis involvement.[161, 162, 163, 164, 165, 166, 167, 168] The most common site of CNS involvement in persons with Langerhans cell histiocytosis is the hypothalamic-pituitary axis, which results in diabetes insipidus in 10-50% of patients.[169] Histiocytosis can be associated with cerebellar white matter abnormalities.[166] Pathologic changes in the cerebellum, basal ganglia, and pons have been reported.[142]

Local involvement of the temporal lobe has also been observed and represents a neurodegenerative disorder that is thought to be similar to a paraneoplastic syndrome.[166] The neurodegenerative changes may occur well before, during, or long after diagnosis of histiocytosis. Manifestation may include cerebellar and pyramidal dysfunction, hormonal abnormalities, ataxia, spasticity, and cognitive problems.[143, 166] MRI abnormalities in cerebellar white matter, brain stem, basal ganglia and cerebral white matter are found.[166]

Involvement of the anterior pituitary is relatively uncommon. However, it can result in growth-hormone deficiency or, in rare cases, panhypopituitarism.[89] Cerebellar dysfunction with incoordination and white matter changes has been reported.[103] Langerhans cell histiocytosis may affect the spleen and liver. Primary involvement of the liver is uncommon.[170, 7] Involvement of the liver is often part of multiorgan disease. Even when PLCs are not present, sclerosing cholangitis can be observed.[170] Liver infiltration may result in tissue damage and increased enzyme levels, jaundice, coagulation disorders, and hypoalbuminemia.

Involvement of the GI tract is probably more common than is clinically recognized.[171] Lesions in the stomach, small bowel, colon, and rectum have been reported.[172, 17, 171, 109, 110] The usual pathology of GI involvement with Langerhans cell histiocytosis includes infiltration of lamina propria and submucosa with glandular, mucosal, and, possibly, villus atrophy. Diarrhea and GI bleeding can be the presenting features of the disease. Involvement of the pancreas is rare.[173, 174]

Langerhans cell histiocytosis rarely involves the intraocular structures. Isolated eye disease has been reported.[138] Lytic lesions of the orbit and resulting soft-tissue extension may cause proptosis. Ptosis and optic atrophy rarely occur. Patients with ear involvement often present with chronic otorrhea, lesions of the external auditory meatus, middle-ear involvement, and mastoid involvement. Although rare, involvement of the genital tract has been reported.[175, 176, 177]

In patients with Langerhans cell histiocytosis and hematopoietic involvement, Langerhans cell infiltration is often not evident; however, other abnormalities are common. These include abnormal M:E ratio; hyperplasia and dysplasia of megakaryocytes, including mononucleated and bilobed micromegakaryocytes and paratrabecular and grouped megakaryocytes; existence of neutrophil remnants in megakaryocytes (emperipolesis); increased numbers of macrophages; hemophagocytosis; and myelofibrosis.[178]

Medical Care

Optimal treatment of Langerhans cell histiocytosis (LCH) has not been established. In ideal cases, the differences between normal cells and pathologic Langerhans cells (PLCs) should be used to guide treatment of the disease. However, a lack of sufficient information has hampered specific therapy.

Substantial variation of the disease and the fact that 10-20% of patients achieve spontaneous regression complicate comparisons of current nonspecific therapies.[179, 180, 181] Several agents, including drugs for cancer chemotherapy, have been effective in the treatment.

Some suggest that treatment of Langerhans cell histiocytosis should be conservative and limited to individuals with constitutional symptoms, such as pain, fever, failure to thrive, and vital organ disorder.[182] Treatment of these disorders must often be tailored to the patient’s prognostic factors, such as the patient’s age, extent of the disease, sites of involvement, and complications. For example, the general agreement is that simple biopsy and curettage are adequate treatment for a solitary bone lesion.[183, 184]

See the Medication section for a discussion of agents used in the treatment of Langerhans cell histiocytosis.


Multidisciplinary care is essential for all patients. Consultation with an oral surgeon and an otolaryngologist, among others, may be required.

Medication Summary

The aim of therapy in histiocytosis is to relieve clinical symptoms and prevent complications of the disease. For single-system disease (eg, of the skin or bone), no therapy or only local therapy may be necessary, although further treatment may be needed in certain circumstances.[49]

Topical therapy

Localized skin lesions, especially in infants, can spontaneously regress. If treatment is required, topical corticosteroids may be tried. Use of extemporaneously prepared topical 0.02% nitrogen mustard has also been advocated.[185, 186, 187] This agent, initially used systemically, appears to provide rapid response within 10 days[186] with minimal adverse effects, such as contact allergy. Scarring at the site of the lesion is thought to be due to the disease and not therapy.[187] In one study, skin lesions promptly healed in 14 of 22 children, and 2 had partial responses.[186] Low-dose radiation therapy to the local lesions is often effective but is rarely needed. For unresponsive skin lesions, low-dose mild systemic therapy can be used.

Chemotherapy for multisystemic disease with local or constitutional symptoms is used.[184] Single agents or adjuvant use of several chemotherapeutic agents and/or biologic-response modifiers may be effective. Published therapies include corticosteroids, vinca alkaloids, antimetabolites-nucleoside analogs, immune modulators such as cyclosporine,[188] antithymocyte globulin,[39] biologic-response modifiers such as interleukin (IL)-2 and interferons (INFs),[189] cellular treatment, and exchange transfusion.[190, 191] Most reports of treatment modalities lack controls, with most authors citing the rarity of the disease as justification for the lack.[57, 192]

Single-agent therapy

Purine analogs with activity for treatment of Langerhans cell histiocytosis (LCH) include 2-chlorodeoxyadenosine (2CdA; cladribine [Leustatin]) and 2-deoxycoformycin (2CDF; pentostatin [Nipent]);[193, 194, 12, 195, 196, 24, 197] 2CdA has been found to be particularly toxic to monocytes.[198] Justification for the use of 2CdA is that some histiocytes are derived from monocytes.[194] In a review of 15 patients with multiorgan involvement receiving 2CdA and 2 receiving 2CDF, 6 had complete responses, 3 had partial responses, 5 had no response, and 1 died early. Fourteen had previously received significant treatments.[193]

As a single agent, cyclosporine has been used in pretreated patients with advanced Langerhans cell histiocytosis. Cyclosporine, a cyclic endecapeptide immunosuppressant of fungal origin, inhibits immune responses. The proposed mechanism of action is blockage of the transmission and synthesis of lymphokines, such as IL-2 and INF (ie, INF-alpha inhibition of the accessory cell function of Langerhans cells and reduced capacity of dendritic cells to enhance mitogenic stimulation of lymphocytes). Cyclosporine is postulated to disrupt abnormal cytokine-dependent activation of lymphocytes and histiocytes in the liver, spleen, lymph nodes, and bone marrow. The activation of lymphocytes is presumed to be secondary to uncontrolled proliferation of Langerhans cells. Furthermore, cyclosporine can inhibit cytokine-mediated cellular activation that potentially contributes to phagocytosis and disease progression.[188]

Partial and complete responses have been recorded in a small number of patients. Patients with partial response had achieved a complete response with prednisone and vinblastine chemotherapy. Cyclosporine A has also been used in familial erythrophagocytic lymphohistiocytosis (FEL). In one report of 2 children whose disease was resistant to steroids and etoposide, durable remission was obtained with this agent.[199]

INF-alpha had some effect in anecdotal cases of Langerhans cell histiocytosis.[200, 189]

Treatment of multifocal relapsing and resistant bone lesions in Langerhans cell histiocytosis is challenging. Langerhans cells are capable of releasing cytokines, which are potent activators of osteoclasts and can result in the lytic lesions seen in the disease. Pamidronate, a bisphosphonate agent, has been reported to induce response or result in disease stability in a very small group of patients.[201]

Multiagent therapy

Most chemotherapy agents for the treatment of Langerhans cell histiocytosis are used in combination. The length of therapy is arbitrarily chosen. In some studies, patients were stratified by risk factor.[202] Use of a combination of cytarabine arabinoside (Ara-C), vincristine, and prednisolone to treat disseminated Langerhans cell histiocytosis with organ dysfunction has been reported.

In a study of 18 pediatric patients with Langerhans cell histiocytosis and multiorgan involvement, 8 had additional organ dysfunction; 8 of 10 patients with organ involvement achieved complete remission.[151] Five of 8 patients with additional dysfunction achieved complete remission. Four (22%) of 18 patients developed diabetes insipidus. Two with organ dysfunction died at the time of the report. The regimen was described as being mildly toxic and relatively well tolerated. In this regimen, cytarabine (100 mg/m2/d for 4 consecutive days), vincristine (1.5 mg/m2 on day 1), and prednisone (40 mg/m2/d for 4 wk followed by 20 mg/m2 for 20 d) were administered. The combination of vincristine and cytarabine was repeated every other week for 4 weeks. Thereafter, the interval was extended by 1 week until this combination was administered every 6 weeks, until complete remission was achieved (4-16 wk).

In a multicenter study in 1983-1988, Italian investigators assigned 70 patients with biopsy-proven Langerhans cell histiocytosis into good-prognosis or poor-prognosis groups, depending on their organ dysfunction.[203] Sixteen patients with limited disease were treated with surgery alone, 5 received immunotherapy with thymus extract then chemotherapy, and 49 patients received chemotherapy with vinblastine (5.5 mg/m2/wk for 3 mo).

Poor responders in this group were then treated with doxorubicin (20 mg/m2 intravenously for 2 d every 3 wk for 3 mo). Patients who did not improve with this regimen were administered etoposide (200 mg/m2 intravenously) for 3 consecutive days every 3 weeks for at least 3 months or until their disease progressed.

The poor-prognosis group (11 patients) received doxorubicin (20 mg/m2 on days 1 and 2), prednisone (40 mg/m2 by mouth on days 1-29), vincristine (1.5 mg/m2 intravenously once a week for 4 wk starting on day 8), and cyclophosphamide(400mg/m2 on days 15 and 29 for 9 courses).

Only 1 of 10 patients with good prognosis had a favorable response during therapy with thymus extract. Of 54 patients receiving chemotherapy (49 as first-line treatment), 34 achieved complete remission with vinblastine, and 8 had a recurrence after 4-22 months. Of 15 patients achieving remission with etoposide, 1 had a relapse 10 months after therapy. In 11 patients with poor prognoses, 7 had progressive disease, and 6 died within 9 months of diagnosis. Organ dysfunction appeared to significantly affect survival, with only 46% of patients surviving for 12 months. The main complication was diabetes insipidus, which occurred in 20% of patients. The overall incidence of disease-related disabilities was 48%.

In the Austrian and German DAL-HX 83/90 study, patients were stratified into 3 groups: those with multifocal bone disease (group A), those with soft-tissue involvement but without organ dysfunction (group B), and those with organ dysfunction (group C).[202] Induction therapy consisted of etoposide (60 mg/m2/d for 5 d on days 1-5, followed by weekly dosing of 150 mg/m2), prednisone (40 mg/m2 on days 1-28), and vinblastine (6 mg/m2 starting at week 3 of therapy). Maintenance therapy was risk related and consisted of vinblastine, 6-mercaptopurine, and prednisone in all patients, with etoposide added in group B and methotrexate and etoposide added in group C. Mortality rates for groups A, B, and C were 8%, 9%, and 38%, respectively.

An organized international approach to LCH has been successful.[184] Using the Histiocyte Society’s Langerhans cell histiocytosis I protocol,[183] investigators prospectively and randomly assigned patients with multisystemic Langerhans cell histiocytosis who met criteria based on standard diagnostic evaluation.[49] Patients received vinblastine (6 mg/m2 intravenously weekly for 24 wk) or etoposide (150 mg/m2 intravenously on 3 consecutive days every 3 wk for 24 wk). All patients received methylprednisolone (30 mg/kg intravenously for 3 consecutive days [maximum daily dose of 1 g]). Of the 447 patients who were registered from various countries, 192 had multisystemic disease, and 136 were randomly assigned (72 to the vinblastine arm and 64 to the etoposide arm).

Patients were evaluated at predetermined intervals. Responses at 6 weeks appeared to differentiate responders from nonresponders, who had poor outcomes. Neither the patients’ ages nor the number, type, or dysfunction of the organs differentiated the groups. At 6 weeks, 51 (50%) of 103 patients achieved a complete response or substantial disease regression, whereas 32 (31%) had stable disease or partial or mixed responses. Disease progression was reported in 19 patients. At 26 months, the mortality rate was 18%. Among the patients who died, 4 had an initial response, 5 had intermediate responses, and 9 had initial nonresponses.

The protocol allowed nonresponders to switch to another treatment arm. Only 34% of patients who had switched had favorable results. Disease recurrence was observed in 11 patients who received vinblastine and in 8 who received etoposide. The 2 arms were statistically similar in terms of initial responses, recurrences, and mortality rates. The overall probability of diabetes insipidus was 42%.

The randomized Langerhans cell histiocytosis II study of the Histiocyte Society was performed to compare the effects of oral prednisone with vinblastine (with or without etoposide) in patients with multisystemic disease. Patients were divided into low- or high-risk groups. All patients received prednisone (40 mg/m2/d for 28 d with weekly reduction afterward) and vinblastine (6 mg/m2 intravenously weekly for 6 wk). The low-risk group received continuation therapy with vinblastine (6 mg/m2 during weeks 9, 12, 15, 18, 21, and 24), as well as 5-day pulses of prednisone during the same weeks. Patients in the low-risk group were excluded from randomization.

Patients in the high-risk group were randomly assigned to treatment A or B. Treatment consisted of an initial 6 weeks of therapy with prednisolone and weekly vinblastine and continuation therapy, pulses of vinblastine and/or oral prednisone as in the low-risk group, and daily doses of 6-mercaptopurine (50 mg/m2 during weeks 6-24). Treatment B was the same as treatment A, with the addition of etoposide (150 mg/m2 administered on day 1 of weeks 9, 12, 15, 18, 21, and 24). Results of this protocol have not yet been published.

The Langerhans cell histiocytosis III of the Histiocyte Society study is designed to determine if methotrexate administered during the initial 2 courses of treatment affects outcomes. In addition, investigators will determine whether maintenance therapy reduces the risk of recurrent disease and improves overall outcomes.

Radiation therapy

Radiation therapy is effective in Langerhans cell histiocytosis. Doses ranging from 750-1500 cGy are usually administered, resulting in good local control of single lesions or metastasis, which can occur in critical areas or cause permanent damage. Fractionated doses of radiotherapy have also been used.[204]

Treatment for recurrent or refractory disease

The severity of the recurrent disease often dictates the type of therapy that is most likely to be helpful. For example, recurrence of an isolated bone lesion can often be treated with nonsteroidal anti-inflammatory drugs (NSAIDs) or intralesional steroid injections. When bone lesions are multiple and cause clinically significant morbidity, systemic therapy can be helpful. In such circumstances, patients often respond to the same drugs that they previously received, such as vinblastine and/or corticosteroids. Extensive recurrence of skin disease, including refractory perianal or vulvar involvement, often requires systemic chemotherapy.

When patients do not have an early (ie, by 6 wk of therapy) response to vinblastine, corticosteroids, methotrexate, 6-mercaptopurine, or even etoposide, alternate therapies should be administered. Although several immunomodulatory agents, such as cyclosporine, have been used in patients with refractory disease, the results have been inconsistent. Cytotoxic chemotherapy often needs to be administered as well.

Several studies, including an international phase II trial, demonstrated notable activity of 2CdA. This agent was originally used to treat patients with refractory hairy-cell leukemia and chronic lymphocytic leukemia. Response rates were more than 50%. 2CdA is both lympholytic and monolytic, making it a potentially ideal drug to use in Langerhans cell histiocytosis, which is characterized by reactive lymphocytic and dendritic and macrophage components. Response rates to 2CdA have been particularly good in patients with extensive skin and bone disease, and in some patients with pulmonary involvement. Overall response rates have been about 30-40% in children. In a study with a small number of adults, the response rate was less than 70%. In 2 reports, a combination of 2CdA and Ara-C seemed to have major effects in a small group of children with refractory disease, but clinically significant grade 4 toxicities and a sepsis-related death were reported.[205, 206]

For some patients whose disease does not respond to 2CdA alone, the combination of 2CdA and high-dose cytarabine has been effective. A similar regimen has also been effective in patients with relapses of acute myelogenous leukemia. Until additional information is obtained with this drug combination, the true response rate and the duration of response are difficult to determine.

Other approaches to the treatment of patients with refractory Langerhans cell histiocytosis that are being tested or developed and include agents such as thalidomide, which is used to inhibit tumor necrosis factor (TNF)-alpha and INF-gamma production.[207] In some studies, only patients with low-risk disease were likely to respond to thalidomide, whereas high-risk patients with organ involvement were not.[208, 121] . Further recognition of NF-kappaB pathway may improve the success of targeted therapy for Langerhans cell histiocytosis.[134, 135]

Targeting humanized antibodies against lineage-specific antigens, such as CD1a antigens on Langerhans cell histiocytosis cells, is another treatment being developed. The application of inhibitors of activated cytokine receptors and their downstream signal-transduction pathways is also an important area of future therapeutic trials. Although hematopoietic stem-cell transplantation has been successful in some patients with refractory Langerhans cell histiocytosis, identifying patients who might benefit from such high-risk therapy is difficult, and this treatment is associated with significant acute and chronic complications.

Specific therapies, including monoclonal antibodies against the CD1a or CD52 epitopes found on Langerhans cells, are emerging.[146, 209]

Local therapy with various agents has been reported. Intralesional infiltration of corticosteroids for treatment of localized Langerhans cell histiocytosis has been advocated.[210]

Myeloablative therapy followed by bone-marrow or stem-cell transplantation in disease refractory to the conventional therapy has been reported.[211] However, reporting of positive results are likely to bias such reports.

Intravenous immunoglobulin has been used to treat neurodegenerative Langerhans cell histiocytosis. However, to the authors’ knowledge, no formal study has been done to conclusively affirm the benefit of such a treatment.

The need to develop effective treatments and, ultimately, strategies to prevention progressive fibrosis of the lung, sclerosing cholangitis, and fibrosis of the liver, and the neurodegenerative pattern of CNS involvement is immense. Additional clinical trials are needed to determine whether agents such as 2CdA or specific inhibitors of fibrosis can improve the outcomes of patients with these complications.

Further Outpatient Care

Long-term follow-up care by a multidisciplinary team with knowledge of Langerhans cell histiocytosis (LCH) is critical for all patients, not just those with extensive multisystem disease or those treated with systemic chemotherapy.

Inpatient & Outpatient Medications

See the Medication section.


Patients with Langerhans cell histiocytosis, especially those with multisystemic disease or multifocal skeletal involvement with a relapsing course, have a significant risk of developing adverse late sequelae from their disease or therapy.

Neurocognitive and psychological problems are more frequently recognized likely because of intensified patient follow-up.

Proliferation of Kupffer cells may accompany the initial hepatic involvement with Langerhans cell histiocytosis and subsequently develop into sclerosing cholangitis. This, in turn, may lead to fibrosis and liver failure. Lung and liver transplantation have been successful in patients who develop organ failure due to progressive fibrosis.

Secondary malignancies are reported in patients with Langerhans cell histiocytosis. Malignancies include secondary leukemias (usually acute myelogenous leukemias) caused by exposures to alkylating agents and, in recent reports, to etoposide. Other cancers include thyroid carcinoma, lymphomas, and CNS tumors.


The location of the lesions and the extent of the disease substantially affect the course of the disease and the patient’s prognosis.


Cameron K Tebbi, MD, Professor of Pediatrics, Chief, Division of Pediatric Hematology-Oncology, University of South Florida College of Medicine; Director, Children's Medical Services, Pediatric Hematology/Oncology, Tampa Division, State of Florida Department of Health

Disclosure: Nothing to disclose.


Robert J Arceci, MD, PhD, Director, Children's Center for Cancer and Blood Disorders, Department of Hematology/Oncology, Co-Director of the Ron Matricaria Institute of Molecular Medicine, Phoenix Children's Hospital; Editor-in-Chief, Pediatric Blood and Cancer; Professor, Department of Child Health, University of Arizona College of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Gary R Jones, MD, Associate Medical Director, Clinical Development, Berlex Laboratories

Disclosure: Nothing to disclose.

Mary L Windle, PharmD, Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Gary D Crouch, MD, Associate Professor, Program Director of Pediatric Hematology-Oncology Fellowship, Department of Pediatrics, Uniformed Services University of the Health Sciences

Disclosure: Nothing to disclose.

Helen SI Chan, MBBS, FRCP(C), FAAP, Associate Senior Scientist, Research Institute; Professor, Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto Faculty of Medicine, Canada

Disclosure: Nothing to disclose.

Chief Editor

Max J Coppes, MD, PhD, MBA, President, BC Cancer Agency, Vancouver

Disclosure: Nothing to disclose.

Additional Contributors

Thomas W Loew, MD Clinical Professor of Pediatrics, Division Director of Pediatric Hematology/Oncology, University of Missouri Children's Hospital

Thomas W Loew, MD is a member of the following medical societies: American Academy of Pediatrics, American Academy of Pediatrics, American College of Physician Executives, American Medical Association, American Society of Clinical Oncology, American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Children's Oncology Group

Disclosure: Genzyme Grant/research funds Independent contractor; Genzyme Honoraria Speaking and teaching; Amicus Grant/research funds Independent contractor; Purdue Pharmaceuticals Grant/research funds Independent contractor


  1. Lahey ME. Prognosis in retinucloendotheliosis in children. J Pediatr. 1962;60:664-71.
  2. Leverkus M, Walczak H, McLellan A, et al. Maturation of dendritic cells leads to up-regulation of cellular FLICE- inhibitory protein and concomitant down-regulation of death ligand- mediated apoptosis. Blood. Oct 1 2000;96(7):2628-31. [View Abstract]
  3. Chu T, D'Angio GJ, Favara BE, Ladisch S, Nesbit M, Pritchard J. Histiocytosis syndromes in children. Lancet. Jul 4 1987;2(8549):41-2. [View Abstract]
  4. Neumann MP, Frizzera G. The coexistence of Langerhans' cell granulomatosis and malignant lymphoma may take different forms: report of seven cases with a review of the literature. Hum Pathol. Oct 1986;17(10):1060-5. [View Abstract]
  5. Katz AM, Rosenthal D, Jakubovic HR, et al. Langerhans cell histiocytosis in monozygotic twins. J Am Acad Dermatol. Jan 1991;24(1):32-7. [View Abstract]
  6. Gonzalez CL, Jaffe ES. The histiocytoses: clinical presentation and differential diagnosis. Oncology (Huntingt). Nov 1990;4(11):47-60; discussion 60, 62. [View Abstract]
  7. Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. Aug 2005;36(3):215-25. [View Abstract]
  8. Caux C, Liu YJ, Banchereau J. Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today. Jan 1995;16(1):2-4. [View Abstract]
  9. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. Mar 19 1998;392(6673):245-52. [View Abstract]
  10. Grewal IS, Flavell RA. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today. Sep 1996;17(9):410-4. [View Abstract]
  11. Lykens J, Wessendarp M, Jordan M. Cytokine overproduction by perforin deficient mice is associated with functional alterations of antigen presenting cells. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina, Oct 2006.
  12. Saven A, Foon KA, Piro LD. 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Ann Intern Med. Sep 15 1994;121(6):430-2. [View Abstract]
  13. Spencer D. Rare single system diseases. Paediatr Respir Rev. Mar 2001;2(1):63-9. [View Abstract]
  14. Lucaya J. Histiocytosis X. Am J Dis Child. Apr 1971;121(4):289-95. [View Abstract]
  15. Risdall RJ, Dehner LP, Duray P, et al. Histiocytosis X (Langerhans' cell histiocytosis). Prognostic role of histopathology. Arch Pathol Lab Med. Feb 1983;107(2):59-63. [View Abstract]
  16. Rasool MN, Ramdial PK. Osseous localization of Rosai-Dorfman disease. J Hand Surg [Br]. Jun 1996;21(3):349-50. [View Abstract]
  17. Idlibi O, Hamoudi AB. Primary histiocytosis X of bowel. Pediatr Pathol. 1984;2:492A.
  18. Minkov M, Steiner M, Arico M. Risk organ involvement at reactivation of Langerhans cell histiocytosis (LCH): frequency, course, and outcome. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina, Oct 2006.
  19. Reddy A, Sapp M, Feldman M, et al. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood. Nov 1 1997;90(9):3640-6. [View Abstract]
  20. Surico G, Muggeo P, Muggeo V, et al. Ear involvement in childhood Langerhans' cell histiocytosis. Head Neck. Jan 2000;22(1):42-7. [View Abstract]
  21. Sai S, Fujii K, Masui F, Kida Y. Solitary eosinophilic granuloma of the sternum. J Orthop Sci. 2005;10(1):108-11. [View Abstract]
  22. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. Jan 14 1993;328(2):106-13. [View Abstract]
  23. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. Apr 15 1991;77(8):1627-52. [View Abstract]
  24. Stine KC, Saylors RL, Williams LL, Becton DL. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol. Oct 1997;29(4):288-92. [View Abstract]
  25. Buelens C, Verhasselt V, De Groote D, et al. Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10. Eur J Immunol. Aug 1997;27(8):1848-52. [View Abstract]
  26. Inaba K, Inaba M, Naito M, Steinman RM. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med. Aug 1 1993;178(2):479-88. [View Abstract]
  27. Bjorck P, Banchereau J, Flores-Romo L. CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells. Int Immunol. Mar 1997;9(3):365-72. [View Abstract]
  28. Komp DM. Long-term sequelae of histiocytosis X. Am J Pediatr Hematol Oncol. Summer 1981;3(2):163-8. [View Abstract]
  29. White W, Garen P. Juvenile xanthogranuloma of the paravertebral soft tissue in infancy: a report of two cases. Pediatr Pathol. Jan-Feb 1991;11(1):105-13. [View Abstract]
  30. Lee BH, George S, Kutok JL. Langerhans cell histiocytosis involving the thymus. A case report and review of the literature. Arch Pathol Lab Med. Jul 2003;127(7):e294-7. [View Abstract]
  31. Vassallo R, Ryu JH, Colby TV, et al. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med. Jun 29 2000;342(26):1969-78. [View Abstract]
  32. Ingulli E, Mondino A, Khoruts A, Jenkins MK. In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med. Jun 16 1997;185(12):2133-41. [View Abstract]
  33. Reis e Sousa C, Stahl PD, Austyn JM. Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med. Aug 1 1993;178(2):509-19. [View Abstract]
  34. Kelly KM, Beverley PC, Chu AC, et al. Successful in vivo immunolocalization of Langerhans cell histiocytosis with use of a monoclonal antibody, NA1/34. J Pediatr. Nov 1994;125(5 Pt 1):717-22. [View Abstract]
  35. Perry MC, Harrison EG Jr, Burgert EO Jr, Gilchrist GS. Familial erythrophagocytic lymphohistocytosis. Report of two cases and clinicopathologic review. Cancer. Jul 1976;38(1):209-18. [View Abstract]
  36. Carstensen H, Ornvold K. The epidemiology of Langerhans cell histiocytosis in children in Denmark 1975-89. Med Pediatr Oncol. 1993;21:387-8.
  37. Mierau GW, Wills EJ, Steele PO. Ultrastructural studies in Langerhans cell histiocytosis: a search for evidence of viral etiology. Pediatr Pathol. Sep-Oct 1994;14(5):895-904. [View Abstract]
  38. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. Aug 1 1995;182(2):389-400. [View Abstract]
  39. Stephan JL, Donadieu J, Ledeist F, et al. Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporine A. Blood. Oct 15 1993;82(8):2319-23. [View Abstract]
  40. Maccheron LJ, McNab AA, Elder J, et al. Ocular adnexal Langerhans cell histiocytosis clinical features and management. Orbit. Sep 2006;25(3):169-77. [View Abstract]
  41. Malone M. The histiocytoses of childhood. Histopathology. Aug 1991;19(2):105-19. [View Abstract]
  42. [Guideline] Arico M, Girschikofsky M, Genereau T, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer. Nov 2003;39(16):2341-8. [View Abstract]
  43. Götz G, Fichter J. Langerhans'-cell histiocytosis in 58 adults. Eur J Med Res. Nov 29 2004;9(11):510-4. [View Abstract]
  44. Strieter RM, Kunkel SL. Acute lung injury: the role of cytokines in the elicitation of neutrophils. J Investig Med. Dec 1994;42(4):640-51. [View Abstract]
  45. Nezelof C, Basset F, Rousseau MF. Histiocytosis X histogenetic arguments for a Langerhans cell origin. Biomedicine. Sep 1973;18(5):365-71. [View Abstract]
  46. Abla O, Egeler RM, Weitzman S. Langerhans cell histiocytosis: Current concepts and treatments. Cancer Treat Rev. Feb 25 2010;[View Abstract]
  47. [Guideline] Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. Dec 1999;17(12):3835-49. [View Abstract]
  48. Arceci RJ. Histiocytoses and disorders of the reticuloendothelial system. In: Handin RI, Lux SE, Stossel TP, eds. Blood: Principles and Practice of Hematology. Philadelphia, Pa: JB Lippincott; 1995:915-46.
  49. Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am. Apr 1998;12(2):327-38. [View Abstract]
  50. Janney CG, Hurt MA, Santa Cruz DJ. Deep juvenile xanthogranuloma. Subcutaneous and intramuscular forms. Am J Surg Pathol. Feb 1991;15(2):150-9. [View Abstract]
  51. Freyer DR, Kennedy R, Bostrom BC, et al. Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. J Pediatr. Aug 1996;129(2):227-37. [View Abstract]
  52. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. Jan 1969;87(1):63-70. [View Abstract]
  53. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. Feb 1990;7(1):19-73. [View Abstract]
  54. Rossbach HC, Dalence C, Wynn T, Tebbi C. Faisalabad histiocytosis mimics Rosai-Dorfman disease: brothers with lymphadenopathy, intrauterine fractures, short stature, and sensorineural deafness. Pediatr Blood & Cancer. Oct/2006;47(5):629-632. [View Abstract]
  55. Skiljo M, Garcia-Lora E, Tercedor J, et al. Purely cutaneous Rosai-Dorfman disease. Dermatology. 1995;191(1):49-51. [View Abstract]
  56. Foucar E, Rosai J, Dorfman RF, Eyman JM. Immunologic abnormalities and their significance in sinus histiocytosis with massive lymphadenopathy. Am J Clin Pathol. Nov 1984;82(5):515-25. [View Abstract]
  57. Komp DM. The treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Semin Diagn Pathol. Feb 1990;7(1):83-6. [View Abstract]
  58. Janka G, Imashuku S, Elinder G, et al. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. Apr 1998;12(2):435-44. [View Abstract]
  59. Jaffe ES, Costa J, Fauci AS, et al. Malignant lymphoma and erythrophagocytosis simulating malignant histiocytosis. Am J Med. Nov 1983;75(5):741-9. [View Abstract]
  60. Boyd AW, Ellis DW, Kannourakis G, et al. Activated killer cell lymphoma: an erythrophagocytic syndrome simulating histiocytic medullary histiocytosis. Pathology. Jul 1988;20(3):265-70. [View Abstract]
  61. Falini B, Pileri S, De Solas I, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood. Jan 15 1990;75(2):434-44. [View Abstract]
  62. Lay JD, Tsao CJ, Chen JY, et al. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest. Oct 15 1997;100(8):1969-79. [View Abstract]
  63. Egeler RM, D'Angio ES, eds. Hematol Oncol Clin North Am. 12:2.
  64. Trizzino A, Janka G, Ueda I. Genotype-phenotype correlations in hemophagocytic lymphohistiocytosis. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina, Oct 2006.
  65. Lu G, Xie ZD, Shen KL, et al. Mutations in the perforin gene in children with hemophagocytic lymphohistiocytosis. Chin Med J (Engl). Dec 5 2009;122(23):2851-5. [View Abstract]
  66. Santoro A, Cannella S, Bossi G. MUNC13-4 mutations in patients with hemophagocytic lymphohistiocytosis are scattered of the functional domains of the protein. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina, Oct 2006.
  67. Arico M, Egeler RM. Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. Apr 1998;12(2):247-58. [View Abstract]
  68. Stark B, Hershko C, Rosen N, et al. Familial hemophagocytic lymphohistiocytosis (FHLH) in Israel. I. Description of 11 patients of Iranian-Iraqi origin and review of the literature. Cancer. Nov 15 1984;54(10):2109-21. [View Abstract]
  69. Ost A, Nilsson-Ardnor S, Henter JI. Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis. Histopathology. Apr 1998;32(4):310-6. [View Abstract]
  70. Filipovich AH. Life-threatening hemophagocytic syndromes: current outcomes with hematopoietic stem cell transplantation. Pediatr Transplant. Dec 2005;9 Suppl 7:87-91. [View Abstract]
  71. Laurencikas E, Hjorth L, Osterlunch G. Frequency and imaging characteristics of CNS abnormalities in children with henmophagocytic lymphohistiocytosis. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina, Oct 2006.
  72. Ishii E, Ueda I, Shirakawa R, et al. Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions. Blood. May 1 2005;105(9):3442-8. [View Abstract]
  73. zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. Mar 15 2005;14(6):827-34. [View Abstract]
  74. Horne A, Rudd E, Ericson K. Characterization of genotype-phenotype correlations in hemophagocytic lymphohistiocytosis. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina, Oct 2006.
  75. Kadin ME, Kamoun M, Lamberg J. Erythrophagocytic T gamma lymphoma: a clinicopathologic entity resembling malignant histiocytosis. N Engl J Med. Mar 12 1981;304(11):648-53. [View Abstract]
  76. Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood. Dec 1 1996;88(11):4265-74. [View Abstract]
  77. Chang KL, Arber DA. Hepatosplenic gamma delta T-cell lymphoma--not just alphabet soup. Adv Anat Pathol. Jan 1998;5(1):21-9. [View Abstract]
  78. Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol. Feb 1991;18(1):29-33. [View Abstract]
  79. Dorfman RF, Berry GJ. Kikuchi's histiocytic necrotizing lymphadenitis: an analysis of 108 cases with emphasis on differential diagnosis. Semin Diagn Pathol. Nov 1988;5(4):329-45. [View Abstract]
  80. Marcenaro S, Gallo F, Martini S. Defective CD107a surface expression heralds MUNC13-4 defect and discriminates between genetic subtypes of familial hemophagocytic lymphohistiocytosis. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina, Oct 2006.
  81. Zunino-Goutorbe C, Eschard C, Durlach A, Bernard P. Congenital solitary histiocytoma: a variant of Hashimoto-Pritzker histiocytosis. A retrospective study of 8 cases. Dermatology. 2008;216(2):118-24. [View Abstract]
  82. Schmidt S, Eich G, Hanquinet S, Tschäppeler H, Waibel P, Gudinchet F. Extra-osseous involvement of Langerhans' cell histiocytosis in children. Pediatr Radiol. Apr 2004;34(4):313-21. [View Abstract]
  83. Tsai JH, Galaydh F, Ching SS. Anterior uveitis and iris nodules that are associated with Langerhans cell histiocytosis. Am J Ophthalmol. Dec 2005;140(6):1143-5. [View Abstract]
  84. Avery ME, McAfee JG, Guild HC. The course and prognosis of reticuloendotheliosis (eosinophilic granuloma, Schuller-Christian disease and Letterer-Siwe disease); a study of forty cases. Am J Med. Apr 1957;22(4):636-52. [View Abstract]
  85. Sims DG. Histiocytosis X; follow-up of 43 cases. Arch Dis Child. Jun 1977;52(6):433-40. [View Abstract]
  86. Greenberger JS, Cassady JR, Jaffe N, et al. Radiation therapy in patients with histiocytosis: management of diabetes insipidus and bone lesions. Int J Radiat Oncol Biol Phys. 5(10):1749-55. [View Abstract]
  87. Braunstein GD, Kohler PO. Endocrine manifestations of histiocytosis. Am J Pediatr Hematol Oncol. Spring 1981;3(1):67-75. [View Abstract]
  88. Rosenzweig KE, Arceci RJ, Tarbell NJ. Diabetes insipidus secondary to Langerhans' cell histiocytosis: is radiation therapy indicated?. Med Pediatr Oncol. Jul 1997;29(1):36-40. [View Abstract]
  89. Kaltsas GA, Powles TB, Evanson J, et al. Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab. Apr 2000;85(4):1370-6. [View Abstract]
  90. McDonald JS, Miller RL, Bernstein ML, Olson JW. Histiocytosis X: a clinical presentation. J Oral Pathol. Nov 1980;9(6):342-9. [View Abstract]
  91. Unlu F, Gurses N, Seckin T, Unal T. Multifocal eosinophilic granuloma with sequential periodontitis-like lesions. J Clin Periodontol. Jun 1997;24(6):384-7. [View Abstract]
  92. Lookingbill DP. Histiocytosis X confined to the skin of the scalp. J Am Acad Dermatol. Jun 1984;10(6):968-9. [View Abstract]
  93. Hashimoto K, Kagetsu N, Taniguchi Y, et al. Immunohistochemistry and electron microscopy in Langerhans cell histiocytosis confined to the skin. J Am Acad Dermatol. Dec 1991;25(6 Pt 1):1044-53. [View Abstract]
  94. Johno M, Oishi M, Kohmaru M, et al. Langerhans cell histiocytosis presenting as a varicelliform eruption over the entire skin. J Dermatol. Mar 1994;21(3):197-204. [View Abstract]
  95. Munn S, Chu AC. Langerhans cell histiocytosis of the skin. Hematol Oncol Clin North Am. Apr 1998;12(2):269-86. [View Abstract]
  96. Kapila PK, Grant-Kels JM, Allred C, et al. Congenital, spontaneously regressing histiocytosis: case report and review of the literature. Pediatr Dermatol. Jul 1985;2(4):312-7. [View Abstract]
  97. Hashimoto K, Pritzker MS. Electron microscopic study of reticulohistiocytoma. An unusual case of congenital, self-healing reticulohistiocytosis. Arch Dermatol. Feb 1973;107(2):263-70. [View Abstract]
  98. Hashimoto K, Schachner LA, Huneiti A, Tanaka K. Pagetoid self-healing Langerhans cell histiocytosis in an infant. Pediatr Dermatol. Mar-Apr 1999;16(2):121-7. [View Abstract]
  99. Ha SY, Helms P, Fletcher M, Broadbent V, Pritchard J. Lung involvement in Langerhans' cell histiocytosis: prevalence, clinical features, and outcome. Pediatrics. Mar 1992;89(3):466-9. [View Abstract]
  100. Donnelly LF, Frush DP. Langerhans' cell histiocytosis showing low-attenuation mediastinal mass and cystic lung disease. AJR Am J Roentgenol. Mar 2000;174(3):877-8. [View Abstract]
  101. Motoi M, Helbron D, Kaiserling E, Lennert K. Eosinophilic granuloma of lymph nodes--a variant of histiocytosis X. Histopathology. Nov 1980;4(6):585-606. [View Abstract]
  102. Sacks SH, Hall I, Ragge N, Pritchard J. Chronic dermal sinuses as a manifestation of histiocytosis X. Br Med J (Clin Res Ed). Apr 26 1986;292(6528):1097-8. [View Abstract]
  103. Rosenfield NS, Abrahams J, Komp D. Brain MR in patients with Langerhans cell histiocytosis: findings and enhancement with Gd-DTPA. Pediatr Radiol. 1990;20(6):433-6. [View Abstract]
  104. Beni-Adani L, Sainte-Rose C, Zerah M, et al. Surgical implications of the thickened pituitary stalk accompanied by central diabetes insipidus. J Neurosurg. Aug 2005;103(2 Suppl):142-7. [View Abstract]
  105. Leahy MA, Krejci SM, Friednash M, et al. Human herpesvirus 6 is present in lesions of Langerhans cell histiocytosis. J Invest Dermatol. Nov 1993;101(5):642-5. [View Abstract]
  106. Hage C, Willman CL, Favara BE, Isaacson PG. Langerhans' cell histiocytosis (histiocytosis X): immunophenotype and growth fraction. Hum Pathol. Aug 1993;24(8):840-5. [View Abstract]
  107. Willman CL, Busque L, Griffith BB, et al. Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med. Jul 21 1994;331(3):154-60. [View Abstract]
  108. Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer Suppl. Sep 1994;23:S37-40. [View Abstract]
  109. Egeler RM, Favara BA, van Meurs M,et al. Cytokine profile in Langerhans cell histiocytosis. Presented at: 15th Annual Meeting of the Histiocyte Society; 1999.
  110. Egeler RM, Favara BE, van Meurs M, et al. Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood. Dec 15 1999;94(12):4195-201. [View Abstract]
  111. Ornvold K, Carstensen H, Larsen JK. Flow cytometric DNA analysis of lesions from 18 children with langerhans cell histiocytosis (histiocytosis x). Am J Pathol. Jun 1990;136(6):1301-7. [View Abstract]
  112. Yu RC, Chu AC. Lack of T-cell receptor gene rearrangements in cells involved in Langerhans cell histiocytosis. Cancer. Mar 1 1995;75(5):1162-6. [View Abstract]
  113. Corbeel L. Langerhans histiocytosis, haemophagocytic syndrome and Epstein-Barr virus infection. Eur J Pediatr. Sep 2004;163(9):570-1. [View Abstract]
  114. Chen CJ, Ho TY, Lu JJ, et al. Identical twin brothers concordant for Langerhans' cell histiocytosis and discordant for Epstein-Barr virus-associated haemophagocytic syndrome. Eur J Pediatr. Sep 2004;163(9):536-9. [View Abstract]
  115. Kuwabara S, Takahashi M. Eosinophilic granuloma of the skull in identical twins--case report. Neurol Med Chir (Tokyo). Dec 1990;30(13):1043-6. [View Abstract]
  116. Halton J, Whitton A, Wiernikowski J. Disseminated Langerhans cell histiocytosis in identical twins unresponsive to recombinant human alpha-interferon and total body irradiation. J Pediatr Hematol Oncol. 1992;14:169-72.
  117. Mader I, Stock KW, Radue EW, Steinbrich W. Langerhans cell histiocytosis in monocygote twins: case reports. Neuroradiology. Feb 1996;38(2):163-5. [View Abstract]
  118. Ruco LP, Stoppacciaro A, Vitolo D, Uccini S, Baroni CD. Expression of adhesion molecules in Langerhans' cell histiocytosis. Histopathology. Jul 1993;23(1):29-37. [View Abstract]
  119. de Graaf JH, Tamminga RY, Kamps WA, Timens W. Expression of cellular adhesion molecules in Langerhans cell histiocytosis and normal Langerhans cells. Am J Pathol. Oct 1995;147(4):1161-71. [View Abstract]
  120. de Graaf JH, Tamminga RY, Kamps WA, Timens W. Langerhans' cell histiocytosis: expression of leukocyte cellular adhesion molecules suggests abnormal homing and differentiation. Am J Pathol. Mar 1994;144(3):466-72. [View Abstract]
  121. McClain K, Herring RA, et al. Evaluation of PET scans to ascertain sites of active disease in Langerhans celll histiocytosis: comparison to conventional radiography and bone scans. Presented at: 21st Annual Meeting of the Histiocyte Society; September 2005; Vancouver, British Columbia.
  122. Slacmeuler M, Geissmann Y, Lepelletier JC, et al. Lack of association between Langerhans cell histiocytosis and human herpes virus 6. Presented at: 15th Annual of the Meeting Histiocyte Society; 1999.
  123. Kallen B, Finnstrom O, Nygren KG, Olausson PO. In vitro fertilization in Sweden: child morbidity including cancer risk. Fertil Steril. Sep 2005;84(3):605-10. [View Abstract]
  124. Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. Apr 1985;45(4):1437-43. [View Abstract]
  125. Komp DM. Langerhans cell histiocytosis. N Engl J Med. Mar 19 1987;316(12):747-8. [View Abstract]
  126. Shahla A, Parvaneh V, Hossein HD. Langerhans cells histiocytosis in one family. Pediatr Hematol Oncol. Jun 2004;21(4):313-20. [View Abstract]
  127. Arico M, Bossi G, Branch del Prever A, et al. Langerhans cell histiocytosis in twins: an update. Presented at: 15th. Annual Meeting, of the Histiocyte Society; 1999.
  128. Chan JK, Lamant L, Algar E, et al. ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood. Oct 1 2008;112(7):2965-8. [View Abstract]
  129. Osband ME, Lipton JM, Lavin P, et al. Histiocytosis-X. N Engl J Med. Jan 15 1981;304(3):146-53. [View Abstract]
  130. Ceci A, de Terlizzi M, Toma MG, et al. Heterogeneity of immunological patterns in Langerhan's histiocytosis and response to crude calf thymic extract in 11 patients. Med Pediatr Oncol. 1988;16(2):111-5. [View Abstract]
  131. Filipovich AH, Mathur A, Kamat D, et al. Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency. 1994;5(2):91-112. [View Abstract]
  132. Pastural E, Barrat FJ, Dufourcq-Lagelouse R, et al. Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. Nat Genet. Jul 1997;16(3):289-92. [View Abstract]
  133. Arico M, Danesino C, Pende D, Moretta L. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol. Sep 2001;114(4):761-9. [View Abstract]
  134. Brown CW, Jarvis JG, Letts M, Carpenter B. Treatment and outcome of vertebral Langerhans cell histiocytosis at the Children's Hospital of Eastern Ontario. Can J Surg. Jun 2005;48(3):230-6. [View Abstract]
  135. Brown RE. The NF-kappaB pathway and the successful application of anti-inflammatory and angiostatic therapy in Langerhans' cell histiocytosis. Br J Haematol. Jul 2005;130(1):147-8. [View Abstract]
  136. Titgemeyer C, Grois N, Minkov M, et al. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. Aug 2001;37(2):108-14. [View Abstract]
  137. Hicks J, Flaitz CM. Langerhans cell histiocytosis: current insights in a molecular age with emphasis on clinical oral and maxillofacial pathology practice. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Aug 2005;100(2 Suppl):S42-66. [View Abstract]
  138. Sikic J, Vukojevic N, Popovic-Suic S, Katusic D. Intraocular histiocytosis in a 12-year-old girl without systemic disease. Coll Antropol. 2005;29 Suppl 1:119-21. [View Abstract]
  139. Braier J, Latella A, Balancini B, et al. Isolated pulmonary langerhans cell histiocytosis presenting with recurrent pneumothorax. Pediatr Blood Cancer. Oct 3 2005;[View Abstract]
  140. Monos T, Levy J, Lifshitz T, et al. Isolated congenital histiocytosis in the palpebral conjunctiva in a newborn. Am J Ophthalmol. Apr 2005;139(4):728-30. [View Abstract]
  141. Matsubayashi T, Miwa Y, Saito I, Matsubayashi R. KL-6: marker for pulmonary involvement in Langerhans cell histiocytosis in infants. J Pediatr Hematol Oncol. Sep 2004;26(9):584-6. [View Abstract]
  142. Grois N, Prosch H, Waldhauser F, et al. Pineal gland abnormalities in Langerhans cell histiocytosis. Pediatr Blood Cancer. Sep 2004;43(3):261-6. [View Abstract]
  143. Cagli S, Oktar N, Demirtas E. Langerhans' cell histiocytosis of the temporal lobe and pons. Br J Neurosurg. Apr 2004;18(2):174-80. [View Abstract]
  144. Wnorowski M, Prosch H, et al. Long-term follow up of neurodegenerative (ND) central nervous system (CNS) Langerhans cell histiocytosis (LCH). Presented at: 21st Annual Meeting of the Histiocyte Society; September 2005; Vancouver, British Columbia, Canada.
  145. Azouz EM, Saigal G, Rodriguez MM, Podda A. Langerhans' cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol. Feb 2005;35(2):103-15. [View Abstract]
  146. McClain KL. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother. Nov 2005;6(14):2435-41. [View Abstract]
  147. Schmitz L, Favara BE. Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. Apr 1998;12(2):221-46. [View Abstract]
  148. Favara BE, Steele A. Langerhans cell histiocytosis of lymph nodes: a morphological assessment of 43 biopsies. Pediatr Pathol Lab Med. Sep-Oct 1997;17(5):769-87. [View Abstract]
  149. Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol. Sep 1997;29(3):157-66. [View Abstract]
  150. Dehner LP. Morphologic findings in the histiocytic syndromes. Semin Oncol. Feb 1991;18(1):8-17. [View Abstract]
  151. Egeler RM, Neglia JP, Puccetti DM, et al. Association of Langerhans cell histiocytosis with malignant neoplasms. Cancer. Feb 1 1993;71(3):865-73. [View Abstract]
  152. Mierau GW, Favara BE, Brenman JM. Electron microscopy in histiocytosis X. Ultrastruct Pathol. Apr-Jun 1982;3(2):137-42. [View Abstract]
  153. Wood PM, Bunge RP. The origin of remyelinating cells in the adult central nervous system: the role of the mature oligodendrocyte. Glia. 1991;4(2):225-32. [View Abstract]
  154. Krenacs L, Tiszalvicz L, Krenacs T, Boumsell L. Immunohistochemical detection of CD1A antigen in formalin-fixed and paraffin-embedded tissue sections with monoclonal antibody 010. J Pathol. Oct 1993;171(2):99-104. [View Abstract]
  155. Emile JF, Wechsler J, Brousse N, et al. Langerhans' cell histiocytosis. Definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples. Am J Surg Pathol. Jun 1995;19(6):636-41. [View Abstract]
  156. [Guideline] Broadbent V, Gadner H, Komp DM, Ladisch S. Histiocytosis syndromes in children: II. Approach to the clinical and laboratory evaluation of children with Langerhans cell histiocytosis. Clinical Writing Group of the Histiocyte Society. Med Pediatr Oncol. 1989;17(6):492-5. [View Abstract]
  157. Seyrig F, Emile JF, et al. Thymic involvement in LCH. A survey of 12 cases. Presented at: 21st Annual Meeting of the Histiocyte Society; September 2005; Vancouver, British Columbia, Canada.
  158. Smets A, Mortele K, de Praeter G, et al. Pulmonary and mediastinal lesions in children with Langerhans cell histiocytosis. Pediatr Radiol. Nov 1997;27(11):873-6. [View Abstract]
  159. Yule SM, Hamilton JR, Windebank KP. Recurrent pneumomediastinum and pneumothorax in Langerhans cell histiocytosis. Med Pediatr Oncol. Aug 1997;29(2):139-42. [View Abstract]
  160. Barthez MA, Araujo E, Donadieu J. Langerhans cell histiocytosis and the central nervous system in childhood: evolution and prognostic factors. Results of a collaborative study. J Child Neurol. Mar 2000;15(3):150-6. [View Abstract]
  161. Sivalingam S, Corkill G, Ellis WG, Claiche JR. Focal eosinophilic granuloma of the temporal lobe. Case report. J Neurosurg. Dec 1977;47(6):941-5. [View Abstract]
  162. Greenwood SM, Martin JS, Towfighi J. Unifocal eosinophilic granuloma of the temporal lobe. Surg Neurol. Jun 1982;17(6):441-4. [View Abstract]
  163. Moscinski LC, Kleinschmidt-DeMasters BK. Primary eosinophilic granuloma of frontal lobe. Diagnostic use of S-100 protein. Cancer. Jul 15 1985;56(2):284-8. [View Abstract]
  164. Penar PL, Kim JH, Chyatte D. Solitary eosinophilic granuloma of the frontal lobe. Neurosurgery. Oct 1987;21(4):566-8. [View Abstract]
  165. Itoh H, Waga S, Kojima T, Hoshino T. Solitary eosinophilic granuloma in the frontal lobe: case report. Neurosurgery. Feb 1992;30(2):295-8. [View Abstract]
  166. van der Knaap MS, Arts WF, Garbern JY, et al. Cerebellar leukoencephalopathy: most likely histiocytosis-related. Neurology. Oct 21 2008;71(17):1361-7. [View Abstract]
  167. Hund E, Steiner H, Jansen O, et al. Treatment of cerebral Langerhans cell histiocytosis. J Neurol Sci. Dec 15 1999;171(2):145-52. [View Abstract]
  168. Bergmann M, Yuan Y, Bruck W, et al. Solitary Langerhans cell histiocytosis lesion of the parieto-occipital lobe: a case report and review of the literature. Clin Neurol Neurosurg. Feb 1997;99(1):50-5. [View Abstract]
  169. Dunger DB, Broadbent V, Yeoman E, et al. The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. N Engl J Med. Oct 26 1989;321(17):1157-62. [View Abstract]
  170. Kaplan KJ, Goodman ZD, Ishak KG. Liver involvement in Langerhans cell histiocytosis: a study of nine cases. Mod Pathol. 1999;12:370-8. [View Abstract]
  171. Nanduri VR, Kelly K, Malone M, et at. Colon involvement in Langerhans' cell histiocytosis. J Pediatr Gastroenterol Nutr. Oct 1999;29(4):462-6. [View Abstract]
  172. Nihei K, Terashima K, Aoyama K, et al. Benign histiocytosis X of stomach. Previously undescribed lesion. Acta Pathol Jpn. 33(3):577-88. [View Abstract]
  173. Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet. Mar 26 1994;343(8900):767-8. [View Abstract]
  174. Yu RC, Attra A, Quinn CM, Krausz T, Chu AC. Multisystem Langerhans' cell histiocytosis with pancreatic involvement. Gut. Apr 1993;34(4):570-2. [View Abstract]
  175. Batey CA, Samayoa LM. Progressive Langerhans' cell histiocytosis presenting as a primary penile lesion. J Urol. Mar 2002;167(3):1433-4. [View Abstract]
  176. Montero AJ, Diaz-Montero CM, Malpica A, et al. Langerhans cell histiocytosis of the female genital tract: a literature review. Int J Gynecol Cancer. May-Jun 2003;13(3):381-8. [View Abstract]
  177. Dietrich JE, Edwards C, Laucirica R, Kaufman RH. Langerhans cell histiocytosis of the vulva: two case reports. J Low Genit Tract Dis. Apr 2004;8(2):147-9. [View Abstract]
  178. Galluzzo L, Rosso D, Braier J. Bone marrow histological findings of LCH patients with hematological involvement. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina, Oct 2006.
  179. Muscolo DL, Slullitel G, Ranalletta M, et al. Spontaneous remission of massive solitary eosinophilic granuloma of the femur. J Pediatr Orthop. Nov-Dec 2003;23(6):763-5. [View Abstract]
  180. Yamaguchi S, Oki S, Kurisu K. Spontaneous regression of Langerhans cell histiocytosis: a case report. Surg Neurol. Aug 2004;62(2):136-40; discussion 140-1. [View Abstract]
  181. Rajendram R, Rose G, Luthert P, et al. Biopsy-confirmed spontaneous resolution of orbital langerhans cell histiocytosis. Orbit. Mar 2005;24(1):39-41. [View Abstract]
  182. McLelland J, Broadbent V, Yeomans E, et al. Langerhans cell histiocytosis: the case for conservative treatment. Arch Dis Child. Mar 1990;65(3):301-3. [View Abstract]
  183. Ladisch S, Gadner H, Arico M, et al. LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society. Med Pediatr Oncol. 1994;23(2):107-10. [View Abstract]
  184. Arceci RJ. Comments from the Editor-in-Chief. J Pediatr Hematol Oncol. Jan-Feb 1999;21(1):1-2. [View Abstract]
  185. Mermann AC, Dargeon HW. The management of certain nonlipid reticuloendothelioses. Cancer. Jan-Feb 1955;8(1):112-22. [View Abstract]
  186. Sheehan MP, Atherton DJ, Broadbent V, Pritchard J. Topical nitrogen mustard: an effective treatment for cutaneous Langerhans cell histiocytosis. J Pediatr. Aug 1991;119(2):317-21. [View Abstract]
  187. Hoeger PH, Nanduri VR, Harper JI, et al. Long term follow up of topical mustine treatment for cutaneous langerhans cell histiocytosis. Arch Dis Child. Jun 2000;82(6):483-7. [View Abstract]
  188. Mahmoud HH, Wang WC, Murphy SB. Cyclosporine therapy for advanced Langerhans cell histiocytosis. Blood. Feb 15 1991;77(4):721-5. [View Abstract]
  189. Sato Y, Ikeda Y, Ito E, et al. Histiocytosis X: successful treatment with recombinant interferon-alpha A. Acta Paediatr Jpn. Apr 1990;32(2):151-4. [View Abstract]
  190. Ladisch S, Ho W, Matheson D, et al. Immunologic and clinical effects of repeated blood exchange in familial erythrophagocytic lymphohistiocytosis. Blood. Oct 1982;60(4):814-21. [View Abstract]
  191. Ladisch S, Gadner H. Treatment of Langerhans cell histiocytosis--evolution and current approaches. Br J Cancer Suppl. Sep 1994;23:S41-6. [View Abstract]
  192. D'Angio GJ. Langerhans cell histiocytosis and etoposide: risks vs. benefits. Med Pediatr Oncol. 1994;23(2):69-71. [View Abstract]
  193. Weitzman S, Wayne AS, Arceci R, et al. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol. Nov 1999;33(5):476-81. [View Abstract]
  194. Saven A, Figueroa ML, Piro LD, Rosenblatt JD. 2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med. Sep 2 1993;329(10):734-5. [View Abstract]
  195. McCowage GB, Frush DP, Kurtzberg J. Successful treatment of two children with Langerhans' cell histiocytosis with 2'-deoxycoformycin. J Pediatr Hematol Oncol. May 1996;18(2):154-8. [View Abstract]
  196. Dimopoulos MA, Theodorakis M, Kostis E, et al. Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine. Leuk Lymphoma. Mar 1997;25(1-2):187-9. [View Abstract]
  197. Randrianasolo MP, Beylot-Barry M, Vergier B, Cipriano G, Jegou-Penouil MH, Doutre MS. Aggressive intermediate cell histiocytosis successfully treated by 2-chlorodeoxyadenosine. J Eur Acad Dermatol Venereol. Sep 2008;22(9):1153-6. [View Abstract]
  198. Carrera CJ, Terai C, Lotz M, et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest. Nov 1990;86(5):1480-8. [View Abstract]
  199. Abella EM, Artrip J, Schultz K, Ravindranath Y. Treatment of familial erythrophagocytic lymphohistiocytosis with cyclosporine A. J Pediatr. Mar 1997;130(3):467-70. [View Abstract]
  200. Jakobson AM, Kreuger A, Hagberg H, Sundstrom C. Treatment of Langerhans cell histiocytosis with alpha-interferon. Lancet. Dec 26 1987;2(8574):1520-1. [View Abstract]
  201. Ramanujachar R, Nanduri V, Thompson D. Bisphonates to the "rescue" of bony lesions and recurrences in Langrhans cell histiocytosis. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina, Oct 2006.
  202. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 138(5):728-34. [View Abstract]
  203. Ceci A, de Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X '83 study. Med Pediatr Oncol. 1993;21(4):259-64. [View Abstract]
  204. Jahraus CD, Russo S, Penagaricano J, et al. Radiotherapy dose fractionation in pediatric Langerhans cell histiocytosis. South Med J. Dec 2004;97(12):1268-9. [View Abstract]
  205. Bernard F, Thomas C, Bertrand Y, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer. Nov 2005;41(17):2682-9. [View Abstract]
  206. Maschan M, Novichkova G, et al. 2-chlordeoxyadenosine and intermediate-dose cytosine arabinoside combinatin therapy for high-risk Langerhans cell histiotytosis (HR-LCH). Presented at: 21st Annual Meeting of the at Histiocyte Society; September 2005; Vancouver, British Columbia, Canada.
  207. Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol. Aug 2005;153(2):254-73. [View Abstract]
  208. Mauro E, Fraulini C, Rigolin GM, Galeotti R, Spanedda R, Castoldi G. A case of disseminated Langerhans' cell histiocytosis treated with thalidomide. Eur J Haematol. Feb 2005;74(2):172-4. [View Abstract]
  209. McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. Dec 6 2005;[View Abstract]
  210. Putters TF, de Visscher JG, van Veen A, Spijkervet FK. Intralesional infiltration of corticosteroids in the treatment of localised langerhans' cell histiocytosis of the mandible Report of known cases and three new cases. Int J Oral Maxillofac Surg. Jul 2005;34(5):571-5. [View Abstract]
  211. Akkari V, Donadieu J, Piguet C, et al. Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Transplant. Jun 2003;31(12):1097-103. [View Abstract]
  212. Bernstrand C, Sandstedt B, Ahstrom L, Henter JI. Long-term follow-up of Langerhans cell histiocytosis: 39 years' experience at a single centre. Acta Paediatr. Aug 2005;94(8):1073-84. [View Abstract]
  213. Torkos A, Czigner J, Kiss JG, et al. Cochlear implantation for treatment-induced ototoxic deafness in Langerhans cell histiocytosis. A case report. Eur Arch Otorhinolaryngol. Jun 2005;262(6):496-500. [View Abstract]
  214. Gayhed D, van't Hooft I, Laurencikas E. Neurophyscological profiles in children with CNS-LCH. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina, Oct 2006.
  215. Garg S, Mehta S, Dormans JP. Langerhans cell histiocytosis of the spine in children. Long-term follow-up. J Bone Joint Surg Am. Aug 2004;86-A(8):1740-50. [View Abstract]
  216. Allen MR, Ninfo V, Viglio A, et al. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) in a girl previously affected by acute lymphoblastic leukemia. Med Pediatr Oncol. Aug 2001;37(2):150-2. [View Abstract]
  217. Arceci RJ. The histiocytoses: the fall of the Tower of Babel. Eur J Cancer. May 1999;35(5):747-67; discussion 767-9. [View Abstract]
  218. Arceci RJ. Treatment options--commentary. Br J Cancer Suppl. Sep 1994;23:S58-60. [View Abstract]
  219. Arceci RJ, Brenner MK, Pritchard J. Controversies and new approaches to treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. Apr 1998;12(2):339-57. [View Abstract]
  220. Arico M. Cyclosporine therapy for refractory Langerhans cell histiocytosis. Blood. Dec 1 1991;78(11):3107. [View Abstract]
  221. Arico M, Janka G, Fischer A, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. Feb 1996;10(2):197-203. [View Abstract]
  222. Bergstresser PR, Toshiyuki K, Xu S, et al. T cell-mediated maturation of dendritic cells in dendritic cells. In: Ricciardi-Castagnoli, ed. Fundamental and Clinical Immunology. New York: Plenum; 1997:65-9.
  223. Braier J, Latella A, Lopez IS. Hepatic involvement in Langerhans cell histiocytosis. Cholestasis, sclerosing cholangitis and liver transplantation. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina, Oct 2006.
  224. Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science. Jun 5 1987;236(4806):1229-37. [View Abstract]
  225. Defrance T, Casamayor-Palleja M, Krammer PH. The life and death of a B cell. Adv Cancer Res. 2002;86:195-225. [View Abstract]
  226. Dufour C, Lanciotti M, Micalizzi C, et al. Non-identical twin sisters concordant for Langerhans cell histiocytosis and discordant for secondary acute promyelocytic leukemia. Med Pediatr Oncol. Jul 2001;37(1):70-2. [View Abstract]
  227. Egeler RM, de Kraker J, Voute PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol. 1993;21(4):265-70. [View Abstract]
  228. Egeler RM, Neglia JP, Arico M, et al. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin North Am. Apr 1998;12(2):369-78. [View Abstract]
  229. Egeler RM, Schipper ME, Heymans HS. Gastrointestinal involvement in Langerhans' cell histiocytosis (Histiocytosis X): a clinical report of three cases. Eur J Pediatr. Feb 1990;149(5):325-9. [View Abstract]
  230. Favara BE, Jaffe R. Pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. Mar 1987;1(1):75-97. [View Abstract]
  231. Filipovich AH. Hemophagocytic lymphohistiocytosis: a lethal disorder of immune regulation. J Pediatr. Mar 1997;130(3):337-8. [View Abstract]
  232. Foucar E, Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. An analysis of 14 deaths occurring in a patient registry. Cancer. Nov 1 1984;54(9):1834-40. [View Abstract]
  233. Foucar E, Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. Current status and future directions. Arch Dermatol. Aug 1988;124(8):1211-4. [View Abstract]
  234. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. May 2001;138(5):728-34. [View Abstract]
  235. Gadner H, Heitger A, Grois N, et al. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol. 1994;23(2):72-80. [View Abstract]
  236. Hidayat AA, Mafee MF, Laver NV, Noujaim S. Langerhans' cell histiocytosis and juvenile xanthogranuloma of the orbit. Clinicopathologic, CT, and MR imaging features. Radiol Clin North Am. Nov 1998;36(6):1229-40, xii. [View Abstract]
  237. Histiocyte Society. Report of the Histiocyte Society workshop on "Central nervous system (CNS) disease in Langerhans cell histiocytosis (LCH)". Med Pediatr Oncol. Aug 1997;29(2):73-8. [View Abstract]
  238. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. Jul 10 1997;388(6638):190-5. [View Abstract]
  239. Isaacs H Jr. Fetal and neonatal histiocytoses. Pediatr Blood Cancer. Aug 2006;47(2):123-9. [View Abstract]
  240. Katz SI, Tamaki K, Sachs DH. Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature. Nov 1979;282(5736):324-6. [View Abstract]
  241. Keidan I, Bielorei B, Berkenstadt H, et al. Prospective evaluation of clinical and laboratory effects of intrathecal chemotherapy on children with acute leukemia. J Pediatr Hematol Oncol. Jun 2005;27(6):307-10. [View Abstract]
  242. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte- derived dendritic cells. J Immunol. Feb 1 2000;164(3):1269-76. [View Abstract]
  243. Kim IT, Lee SM. Choroidal Langerhans' cell histiocytosis. Acta Ophthalmol Scand. Feb 2000;78(1):97-100. [View Abstract]
  244. Komp DM. Therapeutic strategies for Langerhans cell histiocytosis. J Pediatr. Aug 1991;119(2):274-5. [View Abstract]
  245. Koppi TA, Tough-Bement T, Lewinsohn DM, et al. CD40 ligand inhibits Fas/CD95-mediated apoptosis of human blood-derived dendritic cells. Eur J Immunol. Dec 1997;27(12):3161-5. [View Abstract]
  246. Lampert F. Langerhans cell histiocytosis. Historical perspectives. Hematol Oncol Clin North Am. Apr 1998;12(2):213-9. [View Abstract]
  247. Laurencikas E, Stalemark H, et al. Incidence of abnormal magnetic resonance imaging findings of the central nervous system in children with Langerhans cell histiocytosis. Presented at: 21st Annual Meeting of the Histiocyte Society; September 2005; Vancouver, British Columbia Canada.
  248. Lichtenstein L. Histiocytosis X; integration of eosinophilic granuloma of bone, Letterer-Siwe disease, and Schuller-Christian disease as related manifestations of a single nosologic entity. AMA Arch Pathol. Jul 1953;56(1):84-102. [View Abstract]
  249. Lipton JM. The pathogenesis, diagnosis, and treatment of histiocytosis syndromes. Pediatr Dermatol. Oct 1983;1(2):112-20. [View Abstract]
  250. Macatonia SE, Hosken NA, Litton M, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol. May 15 1995;154(10):5071-9. [View Abstract]
  251. Malpas JS. Langerhans cell histiocytosis in adults. Hematol Oncol Clin North Am. Apr 1998;12(2):259-68. [View Abstract]
  252. McClain K, Jin H, Gresik V, et al. Langerhans cell histiocytosis: lack of a viral etiology. Am J Hematol. Sep 1994;47(1):16-20. [View Abstract]
  253. Metcalf D. The colony stimulating factors. Discovery, development, and clinical applications. Cancer. May 15 1990;65(10):2185-95. [View Abstract]
  254. Minkov M, Prosch H, Steiner M, et al. Langerhans cell histiocytosis in neonates. Pediatr Blood Cancer. Nov 2005;45(6):802-7. [View Abstract]
  255. Moll H, Fuchs H, Blank C, Rollinghoff M. Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells. Eur J Immunol. Jul 1993;23(7):1595-601. [View Abstract]
  256. Nicholson HS, Egeler RM, Nesbit ME. The epidemiology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. Apr 1998;12(2):379-84. [View Abstract]
  257. Pirtskhalaishvili G, Shurin GV, Gambotto A, et al. Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J Immunol. Aug 15 2000;165(4):1956-64. [View Abstract]
  258. Rescigno M, Piguet V, Valzasina B, et al. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory respo. J Exp Med. Dec 4 2000;192(11):1661-8. [View Abstract]
  259. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. Sep 27 1996;196(2):137-51. [View Abstract]
  260. Salotti J, Nanduri V, Windebank K. Langerhans cell histiocytosis (LCH) in children in the UK and Eire: an epidemiological survey. Presented at Histiocyte Society 22nd Annual Meeting, Buenos Aires, Argentina, Oct 2006.
  261. Scheicher C, Mehlig M, Dienes HP, Reske K. Uptake of microparticle-adsorbed protein antigen by bone marrow-derived dendritic cells results in up-regulation of interleukin-1 alpha and interleukin-12 p40/p35 and triggers prolonged, efficient antigen presentation. Eur J Immunol. Jun 1995;25(6):1566-72. [View Abstract]
  262. Sprent J, Cai Z, Brunmark A, et al. Constructing artificial antigen-presenting cells from drosophila cells in dendritic cells. In: Ricciardi-Castagnoli, ed. Fundamental and Clinical Immunology. New York, NY: Plenum Press; 1997:249-53.
  263. Steinman RM, Pack M, Inaha K. Dendritic cell development and maturation in dendritic cells. In: Ricciardi-Castagnol, ed. Fundamental and Clinical Immunology. New York, NY: Plenum; 1997:1-5.
  264. Stiakaki E, Giannakopoulou C, Kouvidi E, et al. Congenital systemic Langerhans cell histiocytosis (report of two cases). Haematologia (Budap). 1997;28(4):215-22. [View Abstract]
  265. Subramanian N, Krishnakumar S, Babu K, et al. Adult onset Langerhans cell histiocytosis of the orbit--a case report. Orbit. Jun 2004;23(2):99-103. [View Abstract]
  266. Svensson M, Stockinger B, Wick MJ. Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. J Immunol. May 1 1997;158(9):4229-36. [View Abstract]
  267. Treat JR, Suchin KR, James WD. Topical nitrogen mustard ointment with occlusion for Langerhans' cell histiocytosis of the scalp. J Dermatolog Treat. Jan 2003;14(1):46-7. [View Abstract]
  268. Tuting T, Zorina T, Ma DI, et al. Development of dendritic cell-based genetic vaccines for cancer in dendritic cells. In: Ricciardi-Castagnoli, ed. Fundamental and Clinical Immunology. New York, NY: Plenum; 1997:511-8.
  269. Wang J, Zheng L, Lobito A, et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. Jul 9 1999;98(1):47-58. [View Abstract]
  270. Willems F, Amraoui Z, Vanderheyde N, et al. Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood. Jun 1 2000;95(11):3478-82. [View Abstract]
  271. Wilson CC, Tueting T, Ma D, et al. Activation of dendritic cells by surrogate T-cell interactions leads to enhanced costimulation, secretion of TH1-associated cytokines, and CTL inductive capacity. In: Ricciardi-Castagnoli, ed. Dendritic Cells in Fundamental and Clinical Immunology. New York, NY: Plenum; 1997:335-43.
  272. Writing Group of the Histiocyte Society. Histiocytosis syndromes in children. Writing Group of the Histiocyte Society. Lancet. Jan 24 1987;1(8526):208-9. [View Abstract]

Clinically detectable skull lesions in a child with advanced Langerhans cell histiocytosis (LCH).

Erosion of the gingiva that creates the appearance of premature eruption of the teeth in a young child.

Cutaneous Langerhans cell histiocytosis (LCH) in a child. Skin infiltrates are seen on the face, and the chest has maculoerythematous, petechial, and xanthomatous appearance.

Severe scalp disease in a patient with scaly erythematous patches. Patches of alopecia are present. The lesions were not pruritic.

Radiograph of lytic lesions of the skull reveals a punched-out pattern without evidence of periosteal reaction or marginal sclerosis.

Photomicrograph shows sample of Langerhans cell histiocytosis (LCH) that immunocytochemically stains positive for S-100 protein.

Transmission electron micrograph shows a diagnostic rod-shaped Langerhans Birbeck granule.

Erosion of the gingiva that creates the appearance of premature eruption of the teeth in a young child.

Clinically detectable skull lesions in a child with advanced Langerhans cell histiocytosis (LCH).

Cutaneous Langerhans cell histiocytosis (LCH) in a child. Skin infiltrates are seen on the face, and the chest has maculoerythematous, petechial, and xanthomatous appearance.

Severe scalp disease in a patient with scaly erythematous patches. Patches of alopecia are present. The lesions were not pruritic.

Photomicrograph shows sample of Langerhans cell histiocytosis (LCH) that immunocytochemically stains positive for S-100 protein.

Photomicrograph of Langerhans cell histiocytosis (LCH) stained with hematoxylin and eosin. The characteristic Langerhans cells have reniform or convoluted nuclei and abundant cytoplasm.

Transmission electron micrograph shows a diagnostic rod-shaped Langerhans Birbeck granule.

Transmission electron photomicrograph shows Langerhans cells characterized by convoluted nuclear contours and abundant cytoplasm.

Radiograph of lytic lesions of the skull reveals a punched-out pattern without evidence of periosteal reaction or marginal sclerosis.

Three-dimensional reconstructive view of skull lesions in a child with Langerhans cell histiocytosis.

Class Syndromes
  • Langerhans cell histiocytosis
  • Histiocytosis of mononuclear phagocytes other than Langerhans cells
  • Familial and reactive hemophagocytic lymphohistiocytosis (HLH)
  • Sinus histiocytosis with massive lymphadenopathy (SHML), Rosai-Dorfman disease
  • Juvenile xanthogranuloma (JXG)
  • Reticulohistiocytoma
  • Malignant histiocytic disorders
  • Acute monocytic leukemia (FAB M5)
  • Malignant histiocytosis
  • True histiocytic lymphoma
Class Syndromes
Dendritic-cell related
  • Langerhans cell histiocytosis
  • Xanthogranuloma
Macrophage related
  • HLH, genetic or sporadic
  • SHML
Malignant disorders
  • Monocyte related, monocytic leukemia
  • Dendritic-cell related
  • Localized or macrophage related
  • Disseminated (malignant histiocytosis)
Type of Study Study Involvement With Monostotic Lesion
LaboratoryHemoglobin and/or hematocritMonthlyEvery 6 moNone
Leukocyte count and differential cell countMonthlyEvery 6 moNone
Liver function tests*MonthlyEvery 6 moNone
Coagulation studiesMonthlyEvery 6 moNone
Urine osmolality test after overnight water fastEvery 6 moEvery 6 moNone
RadiographyChest, posteroanterior and lateralMonthlyEvery 6 moNone
Skeletal surveyEvery 6 moNoneOnce at 6 mo
* Measurements of alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase.
Evaluation Indication Follow-Up Interval
Bone-marrow aspiration biopsyAnemia, leukopenia, or thrombocytopenia6 mo
Pulmonary function testsAbnormal chest radiographic findings, tachypnea, intercostal retractions6 mo
Lung biopsy after bronchoalveolar lavage, if available*Abnormal findings on pretreatment chest radiography to rule out infectionNone
Small-bowel series and biopsyUnexplained chronic diarrhea, failure to thrive, malabsorptionNone
Hepatic ERCP, angiography, or biopsyHigh liver enzyme levels and hypoproteinemia not caused by protein-losing enteropathy to rule out active LCH vs liver cirrhosisWhen all evidence of disease resolves but hepatic dysfunction persists
IV gadolinium-enhanced MRI of brain and hypothalamic-pituitaryVisual, neurologic, hormonal abnormalities6 mo
Panoramic radiography of the teeth, mandible, and maxilla; consultation with an oral surgeonOral involvement6 mo
Endocrine investigationGrowth failure, diabetes insipidus, hypothalamic syndromes, galactorrhea, precocious or delayed puberty; hypothalamic and/or pituitary abnormality on CT or MRI None
Consultation with an audiologist and an otolaryngologistAural discharge, impaired hearing6 mo
Note.—ERCP = endoscopic retrograde cholangiopancreatography; IV = intravenous.

* Diagnostic findings on bronchoalveolar lavage obviate lung biopsy.

Cell MarkerLCHSHMLFollicular Dendritic TumorHistiocytic SarcomaAcute Monocytic LeukemiaAnaplastic Large-Cell Lymphoma
Type of Test Stain Mononuclear Phagocytic System Langerhans Cells Interdigitating Dendritic Cells Dendritic Reticulum Cells
Frozen-section enzyme histochemistryNonspecific esterase----
Acid phosphatase+---
5' nucleotidase---+
ImmunohistochemistryCD14 (Leu M3/MY4)++++
CD11 C (Leu M5)++++
CD68 (EBM 11)+---
Paraffin-section immunohistochemistryHLA-DR++++
Mac 387+---
Peanut agglutininDiffuseHalo and dotHalo and dot-
Note.—ATPase = adenosine triphosphatase; HLA = human leukocyte antigen.Table 7. Labeling Pattern of Histiocytes and Dendritic Cells
MarkerHistiocytesLangerhans CellsInterdigitating CellsFollicular Dendritic Cells
S-100 protein0SSW
Alpha-naphthyl acetate esteraseSWWW
Note.—0 = no staining; S = strong and constant; W = weak or inconstant.